Tag: Immunotherapy

Black patients have longer time to treatment discontinuation, similar time to next treatment, slightly improved overall survival than White patients

Primary end point not met, but small subset of advanced pancreatic ductal adenocarcinoma patients showed durable responses

Benefit seen for stage III undifferentiated pleomorphic sarcoma or dedifferentiated or pleomorphic liposarcoma of the extremity and limb girdles

One-year progression-free survival, overall survival was 79.4, 89.6 percent; significantly longer survival seen in patients who achieved resectability

Findings seen in patients previously treated with platinum-based chemotherapy and immunotherapy whose tumors highly expressed CEACAM5

Perioperative nivolumab showed event-free survival benefit from time of surgery compared with neoadjuvant nivolumab

Disparities seen based on income, education, and insurance status for both advanced kidney, bladder cancer

Rates of margin-negative resection and recurrence-free survival similar for neoadjuvant immunotherapy, surgery patients

Age and immune checkpoint inhibitor washout time inversely linked to allograft rejection; survival no different with, without allograft rejection

Gene expression signature predicts irAEs in melanoma patients treated with ipilimumab/nivolumab